Hydrocortisone plus Fludrocortisone for Adults with Septic ShockDjillali Annane, Éric Bellissant, Alain Cariou et al.|New England Journal of Medicine|2018Cited by 894
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trialBruno François, Thorbjørn Grøfte, Simon Lambden et al.|The Lancet Respiratory Medicine|2023Cited by 76
Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trialNicholas Heming, LEROY Olivier, Alain Renault et al.|The Lancet Respiratory Medicine|2024Cited by 48